

Optimapharm Announces Pavle Vukojevic as Chief Medical Officer

Optimapharm, a leading mid-sized, full-service CRO across Europe and North America, is thrilled to announce the appointment of **Pavle Vukojevic** as **Chief Medical Officer**, effective immediately.

With over 25 years of experience in clinical development and a background spanning global pharmaceutical leadership, across various therapeutic areas, Pavle brings his expertise to our team. His deep knowledge of international drug development processes, across Latin and North America, EU/non-EU countries, and India positions him as a key driver of innovation in our operations and service offering.

Pavle has successfully designed and executed clinical programs across multiple therapeutic areas, including rheumatology, autoimmune diseases, and rare indications. His in-depth experience includes medical monitoring, pharmacovigilance oversight, regulatory strategy, and clinical trial safety management. He has played a pivotal role in global drug development initiatives, supporting research for small molecules, biologics, gene therapies, and drug-device combinations.

Beyond his industry expertise, Pavle is an ACRP-certified GCP trainer and a former lecturer at the CRA Academy in Belgrade. He is also the author of “Conducting Clinical Trials in Europe: An Insider’s Analysis”, an expert report published by the Cambridge Healthtech Institute.

"I am very excited to be joining the Optimapharm team! At Optimapharm I can see the commitment to our clients, recognize employee-oriented business practices and culture, and envision the potential for growth and further company development. By working together, I do expect that we will provide value to our clients in clinical research and be a part of bringing new therapeutic options to those in need." – Pavle Vukojevic, Chief Medical Officer, Optimapharm.

In his role, Pavle will lead the Medical Affairs department, overseeing and enhancing medical writing, medical monitoring, and safety operations. He will also drive the continued development of Optimapharm's expertise across key therapeutic areas, including celiac disease, ophthalmology, oncology, cardiovascular endocrinology & metabolism, dermatology, women's health, and rare diseases. As a member of the Senior Leadership Team, Pavle will play a big role in shaping the company's medical and scientific strategy.

"I am thrilled to welcome Pavle to Optimapharm! He brings a wealth of knowledge and life experiences that will further enhance Optimapharm's ability to deliver, with excellence, for our clients and provide guidance and leadership to our internal teams. I am sincerely looking forward to working with Pavle!" – Ivana Waller, CEO at Optimapharm.

About Optimapharm

Optimapharm is a leading, mid-sized, full-service CRO across Europe and North America focused on our People, consistent quality delivery to our clients, and supporting the development of new therapies to improve and save Patients' lives. The company provides successful tailor-made clinical research solutions to Biotech, Pharma, and Medical Device companies in 40 countries.

With 26 strategically located offices, Optimapharm is giving unrivaled access to Patients and Investigators in all countries in Europe and North America, with a total population of over 900 million people. Optimapharm conducts phase I – IV studies in all therapeutic areas, specifically focusing on Oncology/Haemato-oncology, Cardio-metabolic, Respiratory, GI&GU, Immunology/Rheumatology, Dermatology, and complex medical device studies. With very strong operational teams, Optimapharm has a reputation for excellent delivery in all projects, including rescue studies.

To learn more about Optimapharm visit our website: <https://optimapharm.eu/>

###